|
1）Trotter JF. Is disease recurrence still relevant to graft survival? Liver Transplant. 2013; 19: S49-55
|
|
|
|
|
2）Rockville MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation Organ Procurement and Transplantation Network(OPTN) and Scientific Registry of Transplant Recipients(SRTR).OPTN/SRTR 2011 Annual Data Report. 2012
|
|
|
|
|
|
3）OʼGrady JG. Phenotypic expression of recurrent disease after liver transplantation. Am J Transplant. 2010; 10: 1149-54
|
|
|
|
|
4）Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant results of the NIDDK long-term follow-up study. AM J Transplant. 2010; 10: 1420-7
|
|
|
|
|
|
5）Verna EC, Burton JR, OʼLeary JG, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group [abstract].J Hepatol. 2013; 58(suppl 1): S10-1
|
|
|
|
|
|
6）Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746-56
|
|
|
|
|
|
7）Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 2012; 18: 29-37
|
|
|
|
|
|
8）Yalamanchili K, Saadeh S, Klintmalm GB, et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010; 16: 431-9
|
|
|
|
|
|
9）Gane EJ, Patterson S, Strasser SI, et al. Combination of lamivudine and adefovir without hepatitis B immune globulin is sage and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013; 19: 268-74
|
|
|
|
|
|
10）Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitits B virus after liver transplantation. Gastroenterology. 2011; 141: 1212-9
|
|
|
|
|
|
11）Campsen J, Zimmerman M, Trotter J, et al. Liver transplantation for primary biliary cirrhosis: result of aggressive corticosteroid withdrawal. Transplant Proc. 2009; 41: 1707-12
|
|
|
|
|
|
12）Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006; 12: 1813-24
|
|
|
|
|
|
13）Egawa H, Ueda Y, Ichida T, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant. 2011; 11: 518-27
|
|
|
|
|
|
14）Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008; 14: 181-5
|
|
|
|
|
|
15）Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011; 365: 1790-800
|
|
|
|
|
|
16）Rice JP, Lucey MR. Should length of sobriety be a major determinant in liver transplant selection? Curr Opin Organ Transplant. 2013; 18: 259-64
|
|
|
|
|
|
17）Leong J, Im GY. Evakuation and selection of the patient with alcoholic liver disease for liver transplant. Clin Liver Dis. 2012; 16: 851-63
|
|
|
|
|
|
18）Singal AK, Bashar H, Anand BS, et al. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology. 2012; 55: 1398-405
|
|
|
|
|
|
19）De Gottardi A, Spahr L, gelez P, et al. A simple score for predicting alcohol relapse after liver transplantation. Arch Intern Med. 2007; 167: 1183-8
|
|
|
|
|